# MolTrans: Molecular Interaction Transformer for Drug Target Interaction Prediction

### Kexin Huang

Harvard University kexinhuang@hsph.harvard.edu


Cao Xiao

cao.xiao@iqvia.com

### Lucas Glass

IQVIA lucas.glass@iqvia.com


### Jimeng Sun UIUC jimeng@illinois.edu








### **Traditional Drug Discovery & Development Process**



### **Eroom's Law**

### a Overall trend in R&D efficiency (inflation-adjusted)




### **ML Accelerates Drug Discovery**





#### Merck Molecular Activity Challenge

Help develop safe and effective medicines by predicting molecular activity. \$40,000 · 236 teams · 7 years ago



DeepMind's AI will accelerate drug discovery by predicting how proteins fold






T0965 / 6D2V




#### Leading Companies - Advanced AI in Healthcare and Drug Discovery / 2019 Q1




7

**AI-Companies** 

### What's a compound?



## What's a protein?




### Alpha-2A receptor

### Amino Acid Sequence


MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEA PGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVL VIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSL ANEVMGYWYFGKAWCEIYLALDVLFCTSSIVHLCA ISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVIS FPPLISIEKKGGGGGGPQPAEPRCEINDQKWYVISSC IGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDA VAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQ LNGAPGEPAPAGPRDTDALDLEESSSSDHAERPP GPRRPERGPRGKGKARASQVKPGDSLPRRGPGA TGIGTPAAGPGEERVGAAKASRWRGRQNREKRFT FVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFK FFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGD RKRIV

### What's DTI?



### **Q**: Will they bind?


### What's DTI?




### A machine learning question:

Given drug SMILES, target amino acid sequence, what is their predicted binding affinity score?


### **DTI Mechanism**




## **DTI** Application




# A Typical Deep Learning DTI Framework




# Challenge 1: Inadequate modeling of interaction mechanism




# Challenge 2: Restricted to limited labeled data



## MolTrans



### Substructure Decomposition



In order to model the DTI substructural interaction, we have to identify substructure in the input sequence.

## Substructure Decomposition

### A New Data-Driven Algorithm!

Algorithm 1: Frequent Consecutive Sub-sequence Mining **Input:**  $\mathbb{V}$  as the set of all initial amino acids/SMILES tokens;  $\mathbb{W}$ as the set of tokenized proteins/drugs;  $\theta$  as the specified frequency threshold;  $\ell$  as the maximum size of  $\mathbb{V}$ . **Output:** W, the updated tokenized proteins/drugs; V, the updated token vocabulary set. for  $t = 1 \dots \ell$  do (A, B), freq  $\leftarrow$  scan  $\mathbb{W}$ // (A, B) is the frequentest consecutive tokens. if freq  $< \theta$  then // (A, B) 's frequency lower than threshold | break  $\mathbb{W} \leftarrow \text{find}(A, B) \in \mathbb{W}$ , replace with (AB) // update  $\mathbb{W}$  with the combined token (AB) // add (AB) to the token vocabulary set  $\mathbb{V}$  $\mathbb{V} \leftarrow \mathbb{V} \cup (AB)$ 


Partition each SMILES/Amino Acid Sequence into reasonable-sized high-quality substructures.

Mine through vast ChEMBL and UniProt Database!





# Substructure Decomposition Example COTC@@H]1




**Formamide** CO[C@@H]1[C@H](O)[C@@H](C)O[C@@H](OC[C@ @H]2[C@@H](C)OC(=O)\\C=C\\[C@H](C)[C@H](C)[C@H](CC [C@@H](C)C(=O)\\C=C\\[C@H]3O[C@@H]23)O[C@ @H]4O[C@H](C)C[C@H](O)[C@H]4O)[C@@H]1OC

[C@H](O)[C@@H](C) O[C@@H]( OC[C@@H]2 [C@@H](C) OC(=O)\\C=C\\ [C@H](C)[C@H](CC [C@@H](C)C(=O)C=C[C@H]3 O[C@@H]23) O[C@@H]4 O[C@H](C)C[C@H](O) [C@H]4O) [C@@H]1 OC


moderate-sized partition with each partition associated with sub-structures

## Augmented Embedding



To capture relations among each substructure in the input, we leverage Transformer's selfattention mechanism!


## Modeling Sub-structural Interaction



Motivated by the fact that DTI happens in sub-structural level, the interaction module pair each drug-target substructure fingerprint and generate a scalar that measures their interaction,


Each position corresponds to an interaction intensity between a drug and a target substructure!

# Capturing Higher Order Interaction



Nearby sub-structure of proteins and drugs also influence each other in triggering the interactions. We include a convolutional neural network to model these higher-order interactions.

### Prediction



By flattening the CNN output, we generate an embedding for the DTI pair. The embedding is fed into a decoder for prediction.

## MolTrans Achieves Superior Predictive Performance

Dataset 1: BIOSNAP					
Method	ROC-AUC	PR-AUC	Sensitivity	Specificity	Threshold
LR	$0.846 \pm 0.004$	$0.850\pm0.011$	$0.755\pm0.039$	$0.800 \pm 0.018$	0.434
DNN	$0.849 \pm 0.003$	$0.855 \pm 0.010$	$0.776\pm0.040$	$0.838 \pm 0.024$	0.499
GNN-CPI	$0.879 \pm 0.007$	$0.890 \pm 0.004$	$0.780\pm0.014$	$0.819 \pm 0.012$	0.349
DeepDTI	$0.876\pm0.005$	$0.876 \pm 0.006$	$0.789 \pm 0.027$	$0.845 \pm 0.017$	0.347
DeepDTA	$0.876\pm0.005$	$0.883 \pm 0.006$	$0.781 \pm 0.015$	$0.824 \pm 0.012$	0.466
DeepConv-DTI	$0.883 \pm 0.002$	$0.889 \pm 0.005$	$0.770\pm0.023$	$0.832 \pm 0.016$	0.441
MolTrans	$0.895\pm0.002$	$0.901 \pm 0.004$	$0.775\pm0.032$	$0.851 \pm 0.014$	0.431

#### Dataset 2: DAVIS

Method	ROC-AUC	PR-AUC	Sensitivity	Specificity	Threshold
LR	$0.835\pm0.010$	$0.232 \pm 0.023$	$0.699 \pm 0.051$	$0.842 \pm 0.033$	0.399
DNN	$0.864 \pm 0.009$	$0.258 \pm 0.024$	$0.764 \pm 0.045$	$0.860 \pm 0.038$	0.489
GNN-CPI	$0.840\pm0.012$	$0.269 \pm 0.020$	$0.696 \pm 0.047$	$0.842 \pm 0.039$	0.487
DeepDTI	$0.861 \pm 0.002$	$0.231 \pm 0.006$	$0.751 \pm 0.015$	$0.853 \pm 0.012$	0.387
DeepDTA	$0.880\pm0.007$	$0.302\pm0.044$	$0.764\pm0.045$	$0.865 \pm 0.020$	0.482
DeepConv-DTI	$0.884 \pm 0.008$	$0.299 \pm 0.039$	$0.754 \pm 0.040$	$0.880 \pm 0.024$	0.438
MolTrans	$0.907\pm0.002$	$\textbf{0.404} \pm \textbf{0.016}$	$0.800 \pm 0.022$	$0.876 \pm 0.013$	0.447

#### Dataset 3: BindingDB


Method	ROC-AUC	PR-AUC	Sensitivity	Specificity	Threshold
LR	$0.887 \pm 0.002$	$0.557 \pm 0.015$	$0.741 \pm 0.013$	$0.896 \pm 0.011$	0.394
DNN	$0.908 \pm 0.003$	$0.613 \pm 0.015$	$0.769 \pm 0.028$	$0.914 \pm 0.021$	0.371
GNN-CPI	$0.900\pm0.004$	$0.578 \pm 0.015$	$0.754 \pm 0.015$	$0.903 \pm 0.011$	0.406
DeepDTI	$0.844 \pm 0.002$	$0.429 \pm 0.005$	$0.651\pm0.024$	$0.895 \pm 0.023$	0.060
DeepDTA	$0.913 \pm 0.003$	$0.622\pm0.012$	$0.780 \pm 0.035$	$0.915\pm0.016$	0.305
DeepConv-DTI	$0.908 \pm 0.004$	$0.611 \pm 0.015$	$0.781 \pm 0.015$	$0.905 \pm 0.013$	0.318
MolTrans	$0.914 \pm 0.001$	$0.622\pm0.007$	$\left   ext{ 0.797 \pm 0.005 }  ight $	$0.896 \pm 0.007$	0.355

MolTrans has up to 25% increase over best performing baseline!


MolTrans has competitive performance in unseen drug and target setting

Settings	DeepDTI	DeepDTA	DeepConv-DTI	
				$0.853 \pm 0.011$
<b>Unseen Proteins</b>	$0.759 \pm 0.029$	$0.767 \pm 0.022$	$0.766 \pm 0.022$	$0.770 \pm 0.029$

# MolTrans performs best with scarce data




# MolTrans is robust in various protein families



# MolTrans allows model understanding


Drug: 2-nonyl n-oxide

Protein: Cytochrome bc1 complex unit 1 [N+]([O-]) and KNWV has the highest interaction coefficient, matching with the previous study (Lightbown and Jackson, 1956) who showed that nitrogen oxide group is essential for cytochrome inhibition activity.



### Ablation Study

ROC-AUC	PR-AUC	
$0.895 \pm 0.002$	$0.901\pm0.004$	
$0.876 \pm 0.003$	$0.883 \pm 0.006$	
$0.876 \pm 0.004$	$0.870 \pm 0.004$	
$0.847 \pm 0.003$	$0.859 \pm 0.005$	
$0.888 \pm 0.001$	$0.888 \pm 0.007$	
$0.887 \pm 0.004$	$0.887 \pm 0.004$	
	$\begin{array}{c} \textbf{0.895 \pm 0.002} \\ 0.876 \pm 0.003 \\ 0.876 \pm 0.004 \\ 0.847 \pm 0.003 \\ 0.888 \pm 0.001 \end{array}$	



## Thank you!